Abdominal Pain News and Research

RSS

Abdominal pain is traditionally described by its chronicity (acute or chronic), its progression over time, its nature (sharp, dull, colicky), its distribution (by various methods, such as abdominal quadrant (left upper quadrant, left lower quadrant, right upper quadrant, right lower quadrant) or other methods that divide the abdomen into nine sections), and by characterization of the factors that make it worse, or alleviate it.

Amneal's Esomeprazole Strontium 49.3 mg delayed-release capsules now available for GERD patients

Amneal Pharmaceuticals LLC today announced the launch of its branded Esomeprazole Strontium 49.3 mg delayed-release capsules. Esomeprazole Strontium contains the same active moiety (esomeprazole) in a different salt form as found in the branded proton-pump inhibitor Nexium (esomeprazole magnesium) and is a new option for adult patients for the short term treatment of gastroesophageal reflux disease.

17 Dec 2013

New assay allows rapid and sensitive detection of Chlamydia trachomatis

Researchers have developed a new assay for rapid and sensitive detection of Chlamydia trachomatis, the most common sexually transmitted infection (STI) in humans.

12 Dec 2013

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics, Inc. today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA™) at the 55TH Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013.

11 Dec 2013

Endocrinologist suggests parents to check their child's blood sugar more often during holidays

Indulgences abound during the holidays—from family gatherings to parties with friends and even stockings stuffed with goodies from Santa. For children with diabetes, overindulging on the delicacies of the season could result in more than a stomach ache, it could mean a trip to the emergency room.

10 Dec 2013

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a joint panel of members from the Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees of the United States Food and Drug Administration voted to recommend approval of Takeda's vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease.

9 Dec 2013

College students not only bring dirty socks but also mononucleosis to home

One of the hallmarks of heading home for winter break is the enormous amounts of laundry college students bring as a welcome home present for Mom and Dad. But the dirty socks might not be the only unwelcome guest they transport home. They might also bring mononucleosis, better known as mono.

6 Dec 2013

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis will present updates on its broad cancer portfolio with more than 240 abstracts at the upcoming American Society of Hematology (ASH) annual meeting and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

4 Dec 2013

Lexicon announces top-line results from initial Phase 2 study of LX1033 for treatment of IBS-d

Lexicon Pharmaceuticals, Inc. today announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome. LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play a role in the symptoms of irritable bowel syndrome.

3 Dec 2013

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.

23 Nov 2013

First molecular test developed to detect eosinophilic esophagitis

Researchers at Cincinnati Children's Hospital Medical Center have developed the first molecular test to diagnose eosinophilic esophagitis, a chronic upper gastrointestinal disorder. The incidence of EoE has skyrocketed since it was first characterized two decades ago.

22 Nov 2013

Imbruvica gets FDA approval for treatment of mantle cell lymphoma

The U.S. Food and Drug Administration today approved Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma, a rare and aggressive type of blood cancer.

13 Nov 2013

First generic versions of Aciphex delayed-release tablets get FDA approval for GERD treatment

The U.S. Food and Drug Administration today approved the first generic versions of Aciphex (rabeprazole sodium) delayed-release tablets, used to treat gastroesophageal reflux disease in adults and adolescents (ages 12 and up).

10 Nov 2013

BioCryst Pharmaceuticals initiates BCX4161 Phase 2a trial in HAE patients

BioCryst Pharmaceuticals, Inc. today announced that it has dosed the first subject in OPuS-1 (Oral ProphylaxiS-1), a Phase 2a proof of concept clinical trial of orally-administered BCX4161 in patients with hereditary angioedema.

8 Nov 2013

ARIAD temporarily suspends commercial distribution of Iclusig drug in US

ARIAD Pharmaceuticals, Inc. today announced that it is temporarily suspending the marketing and commercial distribution of Iclusig® (ponatinib), a treatment for patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL), in the United States, while it continues to negotiate updates to the U.S. prescribing information for Iclusig and implementation of a risk mitigation strategy.

31 Oct 2013

Researchers identify new drug for treating irritable bowel syndrome with constipation

An international team led by University of Adelaide researchers has identified the mechanism of pain relief of a new drug for treating Irritable Bowel Syndrome with Constipation (IBS-C), based on nonclinical studies, and quantified its effectiveness in pain relief in human trials.

30 Oct 2013

Viewpoints: Republicans new-found interest in the workings of the health website; fixing the problem crucial to Obama's presidency

Republicans are apoplectic about Healthcare.gov, the official Web site for the Affordable Care Act. They are trying desperately to change the subject from their disastrous government shutdown by ranting about the failures of a government Web site that cost a tiny fraction of what was lost as a result of the shutdown. Republicans are pretending that they care about the problems encountered in signing up for a system that many of them are bent on destroying (Charles M. Blow, 10/23).

25 Oct 2013

Endoscopic ultrasound-guided drainage improves outcomes in patients with pseudocysts

Researchers report that in patients with pseudocysts with viscous debris-laden fluid, endoscopic ultrasound-guided drainage by using a combination of a nasocystic drain and transmural stents improves clinical outcomes and lowers the stent occlusion rate compared with those who underwent drainage via stents alone.

22 Oct 2013

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

ARIAD Pharmaceuticals, Inc. today announced that it is discontinuing the Phase 3 EPIC (Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia) trial of Iclusig (ponatinib) in patients with newly diagnosed chronic myeloid leukemia.

18 Oct 2013

Researchers develop simple blood test to identify patient with Irritable Bowel Syndrome

For the first time, a simple blood test may be the best way to determine if a patient is suffering from Irritable Bowel Syndrome, or another serious condition such as Inflammatory Bowel Disease, according to Cedars-Sinai physician researcher Mark Pimentel, MD, lead author of a multicenter clinical trial.

17 Oct 2013

IBS Treatment Center opens new clinic in Santa Monica, California

The IBS Treatment Center, which specializes in treating irritable bowel syndrome, announced the opening of a new clinic in Santa Monica, California, in late October. Conveniently located next to the UCLA Medical Center, this new branch of the clinic will provide a progressive approach to digestive health as well as easy access to treatment for patients previously without adequate care.

15 Oct 2013